Cargando…
A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death. Sorafenib, which is the first-line therapy for this disease, is associated with reduced therapeutic efficacy that could potentially be overcome by combination with selumetinib. In this context, the main goa...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141275/ https://www.ncbi.nlm.nih.gov/pubmed/34040370 http://dx.doi.org/10.2147/IJN.S302288 |